723 related articles for article (PubMed ID: 15942642)
21. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
22. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
[TBL] [Abstract][Full Text] [Related]
23. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
24. [Preparation of NK-enriched LAK cells--their potential cytotoxic and ADCC activities].
Kobayashi Y; Sudo T; Matsushita N; Nakao M; Tanaka Y; Shimizu K; Tanigawa K; Aruga A
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1776-9. PubMed ID: 14619517
[TBL] [Abstract][Full Text] [Related]
25. Role of natural killer cell function in dendritic cell-based vaccines.
Woo CY; Clay TM; Lyerly HK; Morse MA; Osada T
Expert Rev Vaccines; 2006 Feb; 5(1):55-65. PubMed ID: 16451108
[TBL] [Abstract][Full Text] [Related]
26. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
Zheng YJ; Zhang J; Wang SM; Zhang JR
Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
28. X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions.
Ishikawa E; Tsuboi K; Saijo K; Takano S; Ohno T
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1505-12. PubMed ID: 15275738
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
30. Modulation of natural killer cell activity by serum from cancer patients: preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer.
Pislarasu M; Oproiu A; Taranu D; Herberman RB; Sulica A
Cancer Res; 1988 May; 48(9):2596-603. PubMed ID: 3356020
[TBL] [Abstract][Full Text] [Related]
31. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
Vetvicka V; Thornton BP; Wieman TJ; Ross GD
J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
[TBL] [Abstract][Full Text] [Related]
32. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.
Terunuma H; Deng X; Dewan Z; Fujimoto S; Yamamoto N
Int Rev Immunol; 2008; 27(3):93-110. PubMed ID: 18437601
[TBL] [Abstract][Full Text] [Related]
33. [Non-specific killer cells in tumor immune response].
Kumagai K
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):726-33. PubMed ID: 3985642
[TBL] [Abstract][Full Text] [Related]
34. Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy.
Weiss L; Reich S; Mandelboim O; Slavin S
Bone Marrow Transplant; 2004 Jun; 33(11):1137-41. PubMed ID: 15077128
[TBL] [Abstract][Full Text] [Related]
35. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus.
Park YW; Kee SJ; Cho YN; Lee EH; Lee HY; Kim EM; Shin MH; Park JJ; Kim TJ; Lee SS; Yoo DH; Kang HS
Arthritis Rheum; 2009 Jun; 60(6):1753-63. PubMed ID: 19479851
[TBL] [Abstract][Full Text] [Related]
36. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
37. NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells.
Poggi A; Prevosto C; Zancolli M; Canevali P; Musso A; Zocchi MR
Ann N Y Acad Sci; 2007 Aug; 1109():47-57. PubMed ID: 17785290
[TBL] [Abstract][Full Text] [Related]
38. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
[TBL] [Abstract][Full Text] [Related]
39. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
Taguchi T; Domoto K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
[TBL] [Abstract][Full Text] [Related]
40. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
